PCI Pharma Services has begun an expansion of its Tredegar facility in Wales, UK to enhance its drug manufacturing and development capabilities, including both clinical and commercial supply.
The investment involves an extension to the contained oral solid dosage form manufacturing facility that will double the large-scale granulation and fluid bed drying capacity. It will also create additional space for new capabilities and a small-scale processing area to allow early-stage non-GMP processing and formulation.
The new space is expected to be operational in the first half of 2022.
“Pharmaceutical and biopharmaceutical companies are innovating drug treatments today at a rapid pace and in greater volume. As the market continues to grow, we’ve seen an increasing number of clients look to us to provide manufacturing services across the spectrum of dosage forms,” said Richard Yarwood, Chief Scientific Officer at PCI Pharma Services.
The investment in Tredegar follows news earlier this month of the completed expansion to the Rockford, IL facility to include 30,000+ sqft dedicated to speciality drug product capabilities, with four high potent compound capable suites and three new secondary packaging areas.
“This latest investment in Tredegar is part of our ongoing business strategy to remain flexible in an ever-changing marketplace to better service our clients as they work to deliver life-changing therapies to patients,” said Salim Haffar, CEO, PCI Pharma Services.
